

Title: Nivolumab

Reference Number: RDF1147-22

Date of Response: 10/01/23

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

- 1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma? *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Nivolumab (monotherapy)

Answer: ≤5.

Please note the responses provided are for the date range 01/07/2022-31/10/2022. In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients/staff and breach Caldicott principles.

In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed. This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

4.

Nivolumab AND Ipilimumab (combination)

Answer: ≤5.

- 2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal Cell Carcinoma? *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Nivolumab (monotherapy)

Answer: 7.

Nivolumab + Ipilimumab

Answer: Nil.

Nivolumab + Cabozantinib

Answer: Nil.

Avelumab + Axitinib

Answer: Nil.

3. *In the past 3 months, how many patients have been initiated* on the following agents for the treatment of upper gastrointestinal cancer (oesophagael cancer, gastric cancer and gastro-oesophageal junction cancer)? *Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.*

Nivolumab

Answer: Nil.

Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine)?

Answer: ≤5.